LSE:HIK (Hikma Pharmaceuticals Plc)
About HIK
Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd., and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.
Hikma Pharmaceuticals Plc (LSE: HIK) Latest News
Investing Articles
This tax season, consider FTSE 100 dividend stocks to buy for a fresh ISA
Investing Articles
3 epic shares potentially undervalued by 44%
Investing Articles
Income stocks: aim to earn £5,000 while sleeping in 2026
Investing Articles
No savings at 40? Here are 5 cheap shares to consider buying in February
Investing Articles
This FTSE 100 stock could be poised for a whopping 40% growth in 2026, or more
Investing Articles
2 FTSE 100 stocks to consider for passive income in 2026
Investing Articles
Down 33%, is there a once-in-a-decade opportunity in this FTSE 100 stock?
Investing Articles
Down 22% with a P/E of 9, is Hikma one of the best passive income picks right now?
Investing Articles
I asked ChatGPT for the best FTSE 100 stock! Here’s what it said…
Investing Articles
I asked ChatGPT for the best FTSE 100 stocks for a rotation out of tech! Here’s what it said
Investing Articles
Late to investing? Don’t worry… here’s how we aim to build a retirement-boosting ISA